{"id":24497,"date":"2019-04-04T03:00:14","date_gmt":"2019-04-04T03:00:14","guid":{"rendered":"https:\/\/scoliolife.com\/stage\/?p=24497"},"modified":"2022-07-20T03:07:35","modified_gmt":"2022-07-20T03:07:35","slug":"effective-therapeutic-control-of-curve-progression-using-calcium-and-vitamin-d-supplementation-for-adolescent-idiopathic-scoliosis-a-randomized-double-blinded-placebo-controlled-trial","status":"publish","type":"post","link":"https:\/\/scoliolife.com\/stage\/effective-therapeutic-control-of-curve-progression-using-calcium-and-vitamin-d-supplementation-for-adolescent-idiopathic-scoliosis-a-randomized-double-blinded-placebo-controlled-trial\/","title":{"rendered":"Effective therapeutic control of curve progression using calcium and vitamin D supplementation for adolescent idiopathic scoliosis &#8211; a randomized double-blinded placebo-controlled trial"},"content":{"rendered":"<\/p>\n<p>Bone Abstracts (2017) 6 OC8 | DOI: 10.1530\/boneabs.6.OC8<br \/>\nObjectives: Adolescent Idiopathic Scoliosis (AIS) is associated with low bone mass. This study aimed at evaluating the therapeutic effect and its determinants of Ca+Vit-D supplementation in improving bone strength and preventing curve progression in AIS.<\/p>\n<p>Methods: This was a randomized double-blinded placebo-controlled trial recruiting AIS girls (11\u201314 years old, Tanner stage<IV) with femoral neck BMDZ-scores<0 and Cobb angle\u226515\u00b0. 330 subjects were randomized to Group 1 (placebo), Group 2 (600 mg Calcium +400IU Vit-D3\/day) or Group 3 (600mg Calcium +800IU Vit-D3\/day) for 2-year treatment. Investigations at baseline and 2-year included: (1) Finite Element Analysis (FEA) on HR-pQCT at distal radius, (2)serum 25(OH)Vit-D assay and (3) dietary calcium intake. The SRS guideline was followed for the Latest Follow-up analysis on curve progression defined as Cobb increase\u22656\u00b0. P-value<0.05 was considered statistically significant.\n\nResults: 270 (81.8%) subjects completed the study. At 2-year, the increases in FEA parameters were significantly greater in the Treatment Group (Table1).\n\nAt the Latest Follow-up (N=132), 21\u00b77% in Group 3 and 24\u00b74% in Group 2 progressed as compared with 46\u00b77% in Group 1 (P=0.012, 0.032). Within-group logistic regression analysis showed in Group 3, increase in FEA parameters of failure load and apparent modulus were significant protective factors against curve progression (P=0.043 &#038; 0.034 respectively).\n\nFor those with baseline serum 25(OH)Vit-D\u226450 nmol\/l (N=103), 16.2% progressed in Group 3 as compared with 48.6% in Group 1 (P=0.003). For those with 25(OH)Vit-D>50 nmol\/l (N=29), no difference on curve progression was noted. For those with baseline dietary calcium intake \u22641000 mg\/day (N=109), 19.0% progressed in Group 3 as compared with 54.3% in Group 1 (P=0.001). For those with calcium intake>1000 mg\/day (N=23), no difference on curve progression was noted.<\/p>\n<p>Table 1 Mean changes on serum 25(OH)Vit-D level and Finite Element Analysis (FEA) parameters at 2-year for Group 1, 2 and 3.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/scoliolife.com\/stage\/wp-content\/uploads\/2019\/04\/Table-Calcium-EN.jpg\" alt=\"\" width=\"603\" height=\"335\" class=\"alignright size-full wp-image-24498\" srcset=\"https:\/\/scoliolife.com\/stage\/wp-content\/uploads\/2019\/04\/Table-Calcium-EN.jpg 603w, https:\/\/scoliolife.com\/stage\/wp-content\/uploads\/2019\/04\/Table-Calcium-EN-600x333.jpg 600w, https:\/\/scoliolife.com\/stage\/wp-content\/uploads\/2019\/04\/Table-Calcium-EN-300x167.jpg 300w\" sizes=\"(max-width: 603px) 100vw, 603px\" \/><\/p>\n<p><strong>Conclusion: The results of this study provide strong evidences that calcium+Vit-D supplementation can improve bone strength in AIS. Its therapeutic effect on preventing curve progression is correlated with increase in FEA parameters, low baseline 25(OH)Vit-D level and low baseline dietary calcium intake.<\/strong><\/p>\n<p>Funding Source Pfizer Inc (IIRGrant:WI174540). (ClinicalTrials.gov-Identifier: NCT01103115).<\/p>\n<p>Disclosure: The authors declared no competing interests.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bone Abstracts (2017) 6 OC8 | DOI: 10.1530\/boneabs.6.OC8 Objectives: Adolescent Idiopathic Scoliosis (AIS) is associated with low bone mass. This study aimed at evaluating the therapeutic effect and its determinants of Ca+Vit-D supplementation in improving bone strength and preventing curve progression in AIS. Methods: This was a randomized double-blinded placebo-controlled trial recruiting AIS girls (11\u201314 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":546943,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"_links":{"self":[{"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/posts\/24497"}],"collection":[{"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/comments?post=24497"}],"version-history":[{"count":0,"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/posts\/24497\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/media\/546943"}],"wp:attachment":[{"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/media?parent=24497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/categories?post=24497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/scoliolife.com\/stage\/wp-json\/wp\/v2\/tags?post=24497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}